Main Industry
Biotechnology
Main Product/Service
New drug development, custom chemical synthesis, pharmacological activity testing, analytical testing, and development of novel therapeutics targeting irritable bowel syndrome (IBS)-related chronic abdominal pain.
The content above was translated by Ai
Founded Year
2025
Unified Business No.
60713647
Status
Active
Total Paid-in
Capital
10,550,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
LYNTONIX is a biotech startup spun out from a National Taiwan University research team. It focuses on developing non-addictive treatments for chronic pain, particularly irritable bowel syndrome (IBS)-related abdominal pain. Its lead candidate LTX-568 targets a newly discovered pain mechanism and has completed preclinical studies, with plans for IND-enabling studies and clinical trials in the coming years.
The content above was translated by Ai
